1-phenyl-2-aminopent-3-yne | 110079-65-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-phenyl-2-aminopent-3-yne
• 英文别名: 1-Phenylpent-3-yn-2-amine
• CAS: 110079-65-7
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: IMTVBAVVNZRKMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-phenyl-2-aminopent-3-yne 在 Lindlar's catalyst 吡啶 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 15.83h， 生成 N-carbomethoxy-(Z)-1-phenyl-2-aminopent-3-ene
  参考文献：
  名称：

  Total synthesis of carbohydrates. 5. Stereochemistry of the epoxidations of acyclic allylic amides. Applications towards the synthesis of 2,3,6-trideoxy-3-aminohexoses

  摘要：

  DOI：

  10.1021/jo00232a014
• 作为产物：
  描述：

  1-phenylpent-3-yn-2-ol 在 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 23.5h， 生成 1-phenyl-2-aminopent-3-yne
  参考文献：
  名称：

  Total synthesis of carbohydrates. 5. Stereochemistry of the epoxidations of acyclic allylic amides. Applications towards the synthesis of 2,3,6-trideoxy-3-aminohexoses

  摘要：

  DOI：

  10.1021/jo00232a014

文献信息

• NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS.
  申请人：GALAPAGOS NV

  公开号：US20130165437A1

  公开（公告）日：2013-06-27

  A compound according to Formula Ia: wherein L 1 , G, and R 1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  根据以下公式Ia的化合物： 其中L1、G和R1如本文所述。 本发明涉及根据公式I的新化合物，这些化合物对抗GPR84，G蛋白偶联受体，该受体参与炎症病症，以及这些新化合物的生产方法，包含这些化合物的药物组合物，以及通过给予本发明的化合物来预防和/或治疗炎症病症（例如炎症性肠病（IBD）、类风湿关节炎、血管炎、肺部疾病（例如慢性阻塞性肺病（COPD）和肺间质疾病（例如特发性肺纤维化（IPF）））、神经炎症病症、传染病、自身免疫疾病、内分泌和/或代谢疾病，以及/或通过给予本发明的化合物导致免疫细胞功能受损的疾病。
• Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
  申请人：Castro C. Alfredo

  公开号：US20060025460A1

  公开（公告）日：2006-02-02

  One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

  本发明的一个方面涉及结合到bcl蛋白并抑制Bcl功能的杂环化合物。本发明的另一个方面涉及包含本发明的杂环化合物的组合物。本发明提供了用于治疗和调节与过度增殖相关的疾病，如癌症的方法。
• Alkylacetylene substituted Acyltryptophanols
  申请人：Bayer Schering Pharma AG

  公开号：EP2019102A1

  公开（公告）日：2009-01-28

  The present invention relates to acyltryptophanols of the general formula I, in which R1, R2, R3, Q and X have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

  本发明涉及一般式I的酰基色氨酸醇，其中R1、R2、R3、Q和X的含义如描述中所定义。本发明中的化合物是有效的FSH拮抗剂，例如可用于男性或女性的生育控制，或用于骨质疏松症的预防和/或治疗。
• [EN] PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS<br/>[FR] DERIVES DE PHTALAZINE COMME INHIBITEURS DE PHOSPHODIESTERASE 4
  申请人：ZAMBON SPA

  公开号：WO2000005218A1

  公开（公告）日：2000-02-03

  Compounds of formula (I), wherein ------ is a single or double bond; Z is NH, methylene, a (C2-C6)alkylene chain optionally branched and/or unsaturated and/or interrupted by a (C5-C7)cycloalkyl residue; A is phenyl or heterocycle optionally substituted by one or more substituent(s) selected among oxo, nitro, carboxy groups and halogen atoms, or a COR4 group wherein R4 is hydroxy, (C1-C6)-alkoxy, amino optionally substituted by one or two (C1-C6)alkyl group(s) or by hydroxy; R is a (C1-C6)alkyl or polyfluoro(C1-C6)alkyl group; R1 is absent when ------ is a double bond or, when ------ is a single bond, is (a) hydrogen; (b) (C1-C6)alkyl optionally substituted by aryl, by heterocycle or by a COR5 group wherein R5 is hydroxy, (C1-C4)alkoxy or hydroxamino; (c) -COR6 wherein R6 is hydrogen, aryl, aryl-(C1-C6)alkyl, amino optionally alkylated or monohydroxylated, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, formula (1), or (C1-C4)alkyl optionally substituted by heterocycle; (d) (C1-C4)-alkylsulfonyl; R2 represents two hydrogen atoms or a group =O when ------ is a single bond, or, when ------ is a double bond, R2 is hydrogen, cyano, (C1-C4)alkoxycarbonyl, amido, optionally substituted aryl or heterocycle, (C1-C8)alkyl, (C2-C8)alkenyl or (C2-C8)alkynyl optionally branched and/or substituted by aryl or heterocycle; aryloxy, heterocyclyloxy, aryl-(C1-C4)alkoxy, heterocyclyl-(C1-C4) alkoxy, amino substituted by one or two (C1-C4)-alkyl group(s), arylamino, heterocyclylamino, aryl-(C1-C4)alkylamino, heterocyclyl-(C1-C4)-alkylamino; R3 is hydrogen, or a (C1-C8)alkyl, (C2-C8)alkenyl or (C2-C8)alkynyl group optionally substituted by hydroxy, oxo, aryl or heterocycle, and optionally interrupted by one or more heteroatom(s) or heterogroup(s); the N→O derivatives of the compounds of formula (I) and the pharmaceutically acceptable salts thereof are PDE 4 inhibitors.

  化合物的公式（I），其中------是单键或双键；Z是NH，亚甲基，（C2-C6）烷基链，可选地分支和/或不饱和和/或由（C5-C7）环烷基残基中断；A是苯基或杂环，可选地被氧代基，硝基，羧基和卤原子中的一个或多个取代基取代，或者是COR4基团，其中R4是羟基，（C1-C6）烷氧基，氨基，可选地被一种或两种（C1-C6）烷基基团或羟基取代；R是（C1-C6）烷基或聚氟（C1-C6）烷基团；当------是双键时，R1不存在；当------是单键时，R1是（a）氢；（b）（C1-C6）烷基，可选地被芳基，杂环或COR5基团取代，其中R5是羟基，（C1-C4）烷氧基或羟胺基；（c）-COR6，其中R6是氢，芳基，芳基-(C1-C6)烷基，氨基，可选地烷基化或单羟基化，羟基，（C1-C4）烷氧基，羧基，（C1-C4）烷氧基羰基，公式（1），或可选地被杂环取代的（C1-C4）烷基；（d）（C1-C4）烷基磺酰基；R2代表两个氢原子或一个=O基团，当------是单键时，或者当------是双键时，R2是氢，氰基，（C1-C4）烷氧基羰基，酰胺基，可选地被芳基或杂环取代，（C1-C8）烷基，（C2-C8）烯基或（C2-C8）炔基，可选地被芳基或杂环取代和/或分支；芳基氧基，杂环氧基，芳基-(C1-C4)烷氧基，杂环基-(C1-C4)烷氧基，氨基取代的一种或两种（C1-C4）烷基基团，芳基氨基，杂环基氨基，芳基-(C1-C4)烷基氨基，杂环基-(C1-C4)-烷基氨基；R3是氢，或者是（C1-C8）烷基，（C2-C8）烯基或（C2-C8）炔基，可选地被羟基，氧代基，芳基或杂环取代，并且可选地由一个或多个杂原子或杂基中断；公式（I）化合物的N→O衍生物及其药学上可接受的盐是PDE4抑制剂。
• SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES
  申请人：Liang Xifu

  公开号：US20100279936A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C 1-10 heteroaryl, C 6-14 aryl or C 6-10 heterocycloalkylaryl; R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 amino, C 3-6 cycloalkyl, or C 1-6 heterocycloalkyl, each of which are optionally substituted; X represents —CR 3 R 4 —(CR 5 R 6 ) n —(CR 7 ═CR 8 ) m —(C 6-14 aryl) r -(C 1-10 heteroaryl) s -(CR 9 R 10 ) p —(CR 11 ═CR 12 ) q , R 2 represents C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 amino, C 1-12 alkylsilyl, C 6-30 alkylarylsilyl, C 1-10 heteroaryl, C 6-14 aryl, C 1-10 heterocycloalkyl, C 1-10 heterocycloalkenyl, C 1-8 cycloalkyl, C 1-18 cycloalkenyl, each of which is optionally substituted, or R 2 represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.

  该发明涉及新型化合物，其符合公式Ia和Ib;（公式Ia和Ib）其中A代表取代或未取代的C1-10杂环芳基，C6-14芳基或C6-10杂环烷基芳基; R1为C1-6烷基，C2-6烯基，C2-6炔基，C1-6羟基烷基，C1-6卤代烷基，C1-6氨基，C3-6环烷基或C1-6杂环烷基，每个基团都可以取代; X代表—CR3R4—（CR5R6）n—（CR7═CR8）m—（C6-14芳基）r-（C1-10杂环芳基）s-（CR9R10）p—（CR11═CR12）q，R2代表C1-6烷基，C2-6烯基，C2-6炔基，C1-6羟基烷基，C1-6卤代烷基，C1-6氨基，C1-12烷基硅烷基，C6-30烷基芳基硅烷基，C1-10杂环芳基，C6-14芳基，C1-10杂环烷基，C1-10杂环烯基，C1-8环烷基，C1-18环烯基，每个基团都可以取代，或R2代表氢，羧基或羟基;或其药学上可接受的盐，溶剂或酯;用于制备该化合物的工艺，以及用于治疗的化合物，包括该化合物的制药组合物，其中该化合物可用于治疗与CaSR活性紊乱有关的疾病，例如甲状旁腺功能亢进症。